floxuridine has been researched along with Adenocarcinoma in 221 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection." | 9.06 | Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990) |
| "Two cases of recurrent breast cancer, for which combined therapy using toremifene and oral chemotherapeutic agents were effective, are reported." | 7.69 | [Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment]. ( Asanuma, F; Miyagawa, T; Toyoda, H; Uesato, K; Yamada, Y, 1997) |
| "An advanced breast cancer patient refractory to CAF (Cyclophosphamide, Adriamycin, 5-fluorouracil), 5-FU-Methotrexate sequential therapy and Tamoxifen was treated with the combination 5' DFUR, MMC, Etoposide and MPA." | 7.68 | [5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer]. ( Ohtagaki, S; Toge, T; Toi, M; Yagi, M; Yoshinaka, K, 1991) |
| "The present study compared the antitumor activities of chemotherapy with 5-fluorouracil (5-FU) and with its prodrug 5'-deoxy-5-fluorouridine (5'-DFUR) in combination with radiotherapy on a solid colon 26 adenocarcinoma in the mouse." | 7.67 | Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma. ( Ishikawa, T; Ishitsuka, H; Ohkawa, T; Tanaka, Y, 1989) |
| "Fluorine-19 NMR spectrometry was used to monitor the metabolism of two antineoplastic fluoropyrimidines, 5-fluorouracil (5FU) and 5'-deoxy-5-fluorouridine (5'dFUrd), in cell cultures of human pancreatic (Capan-1) and colon (HT-29) adenocarcinoma." | 7.67 | Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. ( Faure, F; Hollande, E; Malet-Martino, MC; Martino, R; Palevody, C; Vialaneix, JP, 1986) |
| "Gemcitabine (dFdC) is a prodrug that undergoes metabolism by cytidine deaminase to form an inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU)." | 5.31 | Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. ( Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG, 2000) |
| " The mean total dosage was 6." | 5.30 | [Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]. ( Baba, H; Kohnoe, S; Matsuoka, H; Morita, M; Saito, T; Seo, Y; Taketomi, A; Tomoda, H, 1997) |
| "5'-Deoxy-5-fluorouridine (DFUR), whether or not combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) was pursued in BDF1 mice from both a pharmacokinetic viewpoint, following a single oral dose administration, and an anticancer viewpoint, following 5 daily oral doses in mice inoculated subcutaneously with adenocarcinoma 755 tumor cells." | 5.28 | Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels. ( De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y; Nishikata, K; Odagiri, H; Okudaira, N, 1989) |
| "Doxifluridine has therapeutic activity, albeit limited, in advanced rectosigmoid adenocarcinoma." | 5.27 | Phase II study of doxifluridine in advanced colorectal adenocarcinoma. ( Abele, R; Alberto, P; Cavalli, F; Hartmann, D; Hofmann, V; Holdener, EE; Kaplan, S; Ryssel, HJ; Siegenthaler, P, 1983) |
| "Thirty-two consecutive patients with a palpable adenocarcinoma of the rectum received preoperative RT (45 Gy in 25 fractions over 5 weeks) plus continuous chemotherapy with doxifluridine and leucovorin or 5-fluorouracil by continuous intravenous infusion during RT." | 5.10 | Preoperative chemoradiation in patients with resectable rectal cancer: results on tumor response. ( Andreola, S; Baratti, D; Bozzetti, F; Mariani, L; Spinelli, P; Stani, SC; Valvo, F, 2002) |
| "We randomly assigned 156 patients at the time of resection of hepatic metastases from colorectal cancer to receive six cycles of hepatic arterial infusion with floxuridine and dexamethasone plus intravenous fluorouracil, with or without leucovorin, or six weeks of similar systemic therapy alone." | 5.09 | Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. ( Bertino, JR; Blumgart, LH; Brennan, MF; Cohen, AM; Conti, JA; Fong, Y; Huang, Y; Kemeny, N; Shi, W; Stockman, J; Sullivan, D; Turnbull, AD, 1999) |
| "Fifty-nine patients with invasive primary gastric adenocarcinoma who were deemed resectable for cure entered a clinical trial that called for 2 cycles of protracted infusion 5-fluorouracil with weekly leucovorin and cisplatin chemotherapy followed by surgery." | 5.08 | Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. ( Baranda, J; Casagrande, Y; Crookes, P; Groshen, S; Laine, L; Leichman, CG; Leichman, L; Silberman, H; Stain, S; Tan, M, 1997) |
| "Because of possibly better activity against colorectal cancer of 5-fluoro-2'-deoxyuridine [floxuridine (FUdR)] compared to 5-fluorouracil (5-FU), and because of improved therapeutic results of leucovorin (LV) modulation of 5-FU, we carried out a phase II study of systemic FUdR and LV in 5-FU-treated patients with metastatic colorectal cancer." | 5.07 | Phase II study of pulse 5-fluoro-2'-deoxyuridine and leucovorin in advanced colorectal cancer patients previously treated with chemotherapy. ( Bertino, JR; Davis, C; Durivage, HJ; Marsh, JC; O'Hollaren, K; Pasquale, DN; Simonich, SA; Voynick, IM, 1992) |
| "Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection." | 5.06 | Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990) |
| "5-Fluorouracil (5-FU) and 5'-deoxy-5-fluorouridine (5'-DFUR), a prodrug of 5-FU, are representative of the chemotherapeutic agents for colorectal adenocarcinomas." | 3.71 | Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo. ( Iwahashi, M; Nagata, T; Nakamori, M; Yamaue, H, 2002) |
| "Two cases of recurrent breast cancer, for which combined therapy using toremifene and oral chemotherapeutic agents were effective, are reported." | 3.69 | [Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment]. ( Asanuma, F; Miyagawa, T; Toyoda, H; Uesato, K; Yamada, Y, 1997) |
| "2,2'-Anhydro-5-ethyluridine (ANEUR), a potent inhibitor of uridine phosphorylase, markedly potentiated the antitumor activity of fluorouridine (FUR) against murine mammary adenocarcinoma 755 in BDF1 mice and human colon adenocarcinoma LS174T in athymic-nude mice." | 3.68 | Differential effects of 2,2'-anhydro-5-ethyluridine, a uridine phosphorylase inhibitor, on the antitumor activity of 5-fluorouridine and 5-fluoro-2'-deoxyuridine. ( De Clercq, E; Iigo, M; Nakajima, Y; Nishikata, K; Szabolcs, A; Szinai, I; Veres, Z, 1990) |
| "An advanced breast cancer patient refractory to CAF (Cyclophosphamide, Adriamycin, 5-fluorouracil), 5-FU-Methotrexate sequential therapy and Tamoxifen was treated with the combination 5' DFUR, MMC, Etoposide and MPA." | 3.68 | [5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer]. ( Ohtagaki, S; Toge, T; Toi, M; Yagi, M; Yoshinaka, K, 1991) |
| "The present study compared the antitumor activities of chemotherapy with 5-fluorouracil (5-FU) and with its prodrug 5'-deoxy-5-fluorouridine (5'-DFUR) in combination with radiotherapy on a solid colon 26 adenocarcinoma in the mouse." | 3.67 | Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma. ( Ishikawa, T; Ishitsuka, H; Ohkawa, T; Tanaka, Y, 1989) |
| "When given orally in combination with L-cysteine, 5'-deoxy-5-fluorouridine (DFUR) brought about a significant reduction in the growth of adenocarcinoma 755 and a significant prolongation of life-span in mice bearing Lewis lung carcinoma without increased toxicity to the host as compared with DFUR alone, though L-cysteine alone did not show an appreciable antitumor activity." | 3.67 | Enhanced antitumor effect of 5'-deoxy-5-fluorouridine by oral administration with L-cysteine. ( Araki, E; Hoshi, A; Iigo, M; Nakajima, Y, 1989) |
| "Fluorine-19 NMR spectrometry was used to monitor the metabolism of two antineoplastic fluoropyrimidines, 5-fluorouracil (5FU) and 5'-deoxy-5-fluorouridine (5'dFUrd), in cell cultures of human pancreatic (Capan-1) and colon (HT-29) adenocarcinoma." | 3.67 | Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. ( Faure, F; Hollande, E; Malet-Martino, MC; Martino, R; Palevody, C; Vialaneix, JP, 1986) |
| "Advanced prostate cancer, which is one of the most common cancers, usually progresses to hormone-refractory prostate cancer (HRPC)." | 2.73 | Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer. ( Honda, J; Kai, N; Kikuchi, K; Kikukawa, H; Kuwahara, T; Matsumoto, K; Nakanishi, J; Takahashi, W; Ueda, S; Wada, Y, 2008) |
| "Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to receive preoperative hepatic and regional arterial chemotherapy (PHRAC group, n = 110) or surgery alone (control group, n = 112)." | 2.73 | Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. ( Jianhua, W; Jiemin, C; Li, R; Weixin, N; Xinyu, Q; Xu, J; Yanhan, L; Zhiping, Y; Zhong, Y, 2007) |
| "Gemcitabine 1,000 mg/m(2) was infused over 100 min (days 1, 8 and 15)." | 2.73 | Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study. ( Bang, SJ; Joo, KR; Kim, H; Kim, MJ; Min, YJ; Nah, YW; Nam, CW; Park, JH; Park, NH; Shin, SJ, 2008) |
| "Sixty gastric cancer patients were divided randomly into three groups (20 each group) before operation: group one:5'-DFUR oral administration at the dose of 800-1200 mg/d for 3 - 5 d, group two: 500 mg 5-FU + 200 mg/d CF by venous drip for 3 - 5 d,group three (control group)." | 2.72 | Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action. ( Ding, W; Luo, B; Ma, ZM; Sheng, JM; Teng, LS; Wang, M; Wang, SF; Wu, FS; Zhao, WH, 2006) |
| "47%, P = 0." | 2.70 | Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. ( Anderson, J; Burton, M; Gebski, V; Gray, B; Hope, M; Moroz, P; Van Hazel, G, 2001) |
| "Median times to disease progression for the three treatment arms were as follows: 9." | 2.69 | Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore ( Lorenz, M; Müller, HH, 2000) |
| "Patients with far advanced colorectal cancers received chemotherapy consisting of low-dose cyclophosphamide (LDCY) 333 mg/m2 every four weeks intravenously and by oral administration of 5'-DFUR (a masked compound of 5-Fluorouracil)." | 2.68 | Effect of low dose cyclophosphamide on the synthesis of acute phase protein and its significance for cancer chemotherapy. ( Fujiwara, T; Hizuta, A; Iwagaki, H; Orita, K; Perdomo, JA; Tanaka, N, 1996) |
| "A clinical trial for patients with gastric cancer amenable to curative resection was undertaken to determine feasibility and response to preoperative systemic chemotherapy followed by postoperative intraperitoneal (IP) chemotherapy." | 2.67 | Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. ( Kiyabu, M; Laine, L; Leichman, CG; Leichman, L; Muggia, FM; Radin, R; Ray, M; Silberman, H; Spears, CP; Stain, S, 1992) |
| " The dosage was 0." | 2.66 | Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Results of a controlled clinical trial. ( Beger, GH; Bittner, R; Gaus, W; Roscher, R; Safi, F; Schuhmacher, K, 1989) |
| "Doxifluridine is an active agent in colorectal cancer." | 2.66 | A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma. ( Alberto, P; Cavalli, F; Germano, G; Joss, R; Kaplan, S; Martz, G; Mermillod, B; Spati, B; Weber, W, 1988) |
| " The elimination half-life time for 5-FU was protracted by a factor of 2-3 compared with the direct injection of 5-FU." | 2.66 | Phase I/II tolerability/pharmacokinetic study with one-hour intravenous infusion of doxifluiridine (5'-dFUrd) 3 g/m2 VS 5 g/m2 QD x 5 per month. ( Aas, M; Flokkmann, A; Fosså, SD; Heier, M; Heintz, R; Linder-Ciccolunghi, S; Moe, B, 1986) |
| " Continuous floxuridine infusion was given at a dosage of 0." | 2.66 | Regional infusion for colorectal hepatic metastases. A randomized trial comparing the hepatic artery with the portal vein. ( Daly, JM; Kemeny, N; Oderman, P; Sigurdson, E; Thom, A, 1987) |
| "Postoperatively cecal cancer was detected." | 2.39 | [Peritoneal dissemination of cecal cancer disappearing in a patient taking 5'-DFUR for 3 years]. ( Etoh, T; Maeda, Y; Matoba, N; Nagata, T; Niiyama, H; Yoshida, J, 1994) |
| "Mean time from gastric cancer diagnosis to liver metastasis was significantly longer in the TAI group (n = 13) than in the systemic chemotherapy group (n = 29); 944 ± 231 days versus 506 ± 77 days." | 1.38 | The effect of locoregional transarterial infusion chemotherapy on liver metastasis after gastric cancer resection. ( Kan, ZX; Liu, R; Qian, S; Wang, JH; Wang, YY; Zhang, W, 2012) |
| "Several factors may influence pancreatic cancer resistance, and expression of ATP-binding cassette transport proteins is one of the major mechanisms of drug resistance." | 1.37 | Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. ( Grube, M; Guitton, J; Hübner, T; Jedlitschky, G; Köck, K; Kowalczyk, DW; Kroemer, HK; Lerch, MM; Mayerle, J; Mews, S; Nambaru, PK; Payen, L; Rimmbach, C; Ritter, CA; Rosskopf, D; Sendler, M; Weiss, FU, 2011) |
| " The pharmacokinetic analysis of gemcitabine and dFdU was performed with high-performance liquid chromatography-tandem mass spectrometry assay in cycles 1 and 2." | 1.35 | Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function. ( Citro, G; Cognetti, F; Colantonio, S; Contestabile, M; Di Segni, S; Felici, A; Milella, M; Nuvoli, B; Sacconi, A; Sperduti, I; Zaratti, M, 2009) |
| "In order to develop a model of liver metastasis of human gastrointestinal cancer cells, we examined the potential of 10 human colon and stomach cancer cell lines (HT-29, WiDr, HCT-116, HCT-15, HCC-2998, MKN7, MKN28, MKN45, MKN74 and St-4) to form liver metastases in nude mice." | 1.34 | Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. ( Ishizu, K; Makuuchi, H; Sadahiro, S; Sunose, N; Tsuruo, T; Yamazaki, K; Yamori, T, 2007) |
| "We report a case of advanced gastric cancer with metastasis to the paraaortic lymph nodes that showed a remarkable response to treatment with a combination of weekly paclitaxel and doxifluridine (5'-DFUR)." | 1.32 | [A case of advanced gastric cancer successfully treated with neoadjuvant chemotherapy of combined weekly paclitaxel and doxifluridine (5'-DFUR)]. ( Hata, T; Hikino, H; Kanazawa, A; Nagaoka, S; Nakamura, K; Ozaki, N; Sugimoto, S; Tokuka, A; Yamada, T, 2004) |
| "In the field of gastric cancer treatment, especially for patients showing multiple resistance to anticancer drugs, an effective therapy is critically needed." | 1.31 | Effectiveness of doxifluridine (5'-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens. ( Kurihara, M; Matsukawa, M; Nakamachi, M; Sato, A; Shimada, K; Ushio, J; Yamamoto, W, 2002) |
| "We report a case of advanced gastric cancer with multiple liver metastases and peritoneal dissemination." | 1.31 | [Effectiveness of high-dose, intermittent 5'-DFUR therapy for advanced gastric cancer]. ( Emoto, K; Etoh, T; Ichiba, Y; Imaoka, Y; Ishizaki, Y; Sumimoto, R; Takahashi, M; Tokumoto, N, 2001) |
| "Gemcitabine (dFdC) is a prodrug that undergoes metabolism by cytidine deaminase to form an inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU)." | 1.31 | Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. ( Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG, 2000) |
| "We report a case of unresectable rectal cancer in a 53-year-old male treated with chemoradiation." | 1.31 | [Long-term complete response in a case of unresectable rectal cancer following chemoradiation]. ( Musha, N; Oka, K; Saito, H; Sando, N; Sasaki, M; Setu, M; Setu, Y; Sunami, E, 2000) |
| "We report a 68-year-old man with rectal cancer and recurrent pulmonary metastasis treated with concomitant 5'-DFUR + MMC, which resulted in an extreme reduction of the lesion." | 1.30 | [Combination of 5'-DFUR and MMC for recurrent rectal cancer with pulmonary metastasis]. ( Aihara, S; Hiki, Y; Ishikawa, H; Kakita, A; Kanazawa, H; Ohtani, Y, 1999) |
| " The mean total dosage was 6." | 1.30 | [Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]. ( Baba, H; Kohnoe, S; Matsuoka, H; Morita, M; Saito, T; Seo, Y; Taketomi, A; Tomoda, H, 1997) |
| "Its efficacy for lung metastases from colorectal cancer is known." | 1.30 | [PyNPase activity in primary and metastatic colorectal cancer]. ( Doi, O; Furukawa, H; Hiratsuka, M; Imaoka, S; Ishikawa, O; Iwanaga, T; Kabuto, T; Kameyama, M; Nakamori, S; Ohigashi, H; Sasaki, Y; Yasuda, T; Yokouchi, H, 1997) |
| "Invest, 101: 344-352, 1998) to suppress pancreatic cancer cell growth and increase cytotoxic actions of cisplatinum." | 1.30 | Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. ( Arber, N; Beger, HG; Danenberg, KD; Danenberg, PV; Korc, M; Kornmann, M, 1999) |
| "Fifty-three patients with advanced colorectal cancer were given single oral doses of 5'-DFUR, 400 mg/body, preoperatively to assess the pharmacokinetics of 5'-DFUR in the patients with colorectal cancer and to investigate schedules for 5'-DFUR treatment." | 1.29 | [Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer]. ( Hanyu, F; Hayashi, T; Igarashi, T; Suzuki, M; Watanabe, K; Yoshida, K, 1994) |
| "A 64-year-old male was found to have a gastric cancer (Borrmann type 3) on the posterior wall of the stomach." | 1.29 | [A case of advanced gastric cancer with liver metastasis disappeared by oral administration of 5'-deoxy-5-fluorouridine after absolute non-curative operation]. ( Matoba, N; Nagata, T; Niiyama, H; Yoshida, J, 1994) |
| "A recurrence of colon cancer developed in the left lower lung 16 months after surgery, and 5'-DFUR was administered at a dose of 1,600 mg/body/day." | 1.29 | [A case of pulmonary metastasis from colon cancer successfully treated with high-dose 5'-DFUR]. ( Fujimoto, T; Iihara, K; Kitada, M; Murotani, M; Okumura, Y; Shibata, T; Takada, T; Takami, M; Tsukahara, Y; Watanabe, T, 1995) |
| "A 71-year-old man with Borrmann type 3 gastric cancer with multiple liver metastases had been treated with 5'-DFUR 1400 mg/m2/day, p." | 1.29 | [A successful 5'-DFUR and CDDP combination therapy for an advanced gastric cancer complicated with multiple liver metastases]. ( Ishihata, R; Kasukawa, R; Kuwana, T; Nishimaki, T; Obara, K, 1995) |
| "We reported a patient with advanced gastric cancer and a liver metastasis, who responded remarkably to combination chemotherapy using THP, 5'-DFUR and CDDP." | 1.29 | [A case of advanced gastric cancer successfully treated with combination chemotherapy using THP, 5'-DFUR and CDDP, followed by surgical resection]. ( Adachi, H; Kobori, O; Kurihara, M; Kurihara, T; Murakami, H; Saito, K; Tamura, Y, 1995) |
| "We describe a case of gastric cancer with multiple liver metastasis that clearly decreased in size after administration of 5'-DFUR." | 1.28 | [A case report; 5'-DFUR reduced gastric cancer with multiple liver metastasis]. ( Itoh, N; Kurimoto, N; Tamura, T; Yasuzawa, Y; Yoshimoto, I, 1992) |
| "However, metastatic bone tumors from gastric cancer usually resist any treatments." | 1.28 | [A case of gastric cancer with recurrent bone metastases successfully treated with induced hypertension chemotherapy using cisplatin]. ( Furuya, K; Kashu, Y; Kiyasu, Y; Moriuchi, A; Sakai, K; Satoh, H; Shigematsu, S; Tanaka, T, 1992) |
| "In 31 evaluable cases with ovarian cancer, the overall efficacy rate was 16." | 1.28 | [Phase II study of 5'-DFUR in uterine cervical cancer and ovarian cancer]. ( Ikeda, M; Noda, K; Ochiai, K; Saito, Y; Sato, A; Suzuki, M; Takada, M; Terashima, Y; Yajima, A; Yoshida, K, 1991) |
| "A woman born in 1924 with colon cancer initially operated on approximately four years ago showed a second recurrence in the lung." | 1.28 | [A case of pulmonary metastasis from colon cancer responding completely to high-dose 5'-DFUR plus MMC combination chemotherapy]. ( Kawahara, T; Kikkawa, N; Kobayakawa, K; Tsuchiya, Y; Tsumura, I, 1991) |
| " This was deemed due to the small dosage and a short duration of 5'-DFUR." | 1.28 | [A study on preoperative administration of doxifluridine in carcinoma of the colon and rectum]. ( Harada, T; Hirano, M; Kikkawa, H; Masuda, S; Matsu, T; Saito, H; Sakatoku, M; Tatsuzawa, T, 1990) |
| "5'-Deoxy-5-fluorouridine (DFUR), whether or not combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) was pursued in BDF1 mice from both a pharmacokinetic viewpoint, following a single oral dose administration, and an anticancer viewpoint, following 5 daily oral doses in mice inoculated subcutaneously with adenocarcinoma 755 tumor cells." | 1.28 | Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels. ( De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y; Nishikata, K; Odagiri, H; Okudaira, N, 1989) |
| "A 68-year-old male, who had advanced rectal cancer with multiple pulmonary metastases, had undergone resection of rectal cancer operatively and was treated with a combination chemotherapy using 5'-DFUR (5'-deoxy-5-fluorouridine) and MMC (mitomycin C) for multiple pulmonary metastases." | 1.28 | [A case of multiple pulmonary metastases from rectal cancer which responded completely to combination chemotherapy using 5'-DFUR and MMC]. ( Baba, K; Kawano, H; Matsuda, M; Matsuoka, Y; Morinaga, H; Nagao, K; Nagase, H; Nishimura, R; Ueno, Y, 1989) |
| "5'-DFUR was administered orally at 800 mg/day, for total dosage of 57." | 1.28 | [A resected case of gastric carcinoma with complete remission of Virchow's node metastasis by 5'-DFUR administration]. ( Fukuda, H; Kitahara, T; Nagamine, H; Nakaguchi, K; Nakano, Y; Onoe, K, 1990) |
| "Doxifluridine has therapeutic activity, albeit limited, in advanced rectosigmoid adenocarcinoma." | 1.27 | Phase II study of doxifluridine in advanced colorectal adenocarcinoma. ( Abele, R; Alberto, P; Cavalli, F; Hartmann, D; Hofmann, V; Holdener, EE; Kaplan, S; Ryssel, HJ; Siegenthaler, P, 1983) |
| "Retreatment of patients with colon cancer and liver metastases by hepatic arterial infusion of fluorodeoxyuridine and mitomycin C can result in significant prolongation of survival in patients with response to this treatment." | 1.27 | Effective retreatment of patients with colorectal cancer and liver metastases. ( Chuang, VP; Mavligit, G; Patt, YZ; Peters, RE; Wallace, S, 1983) |
| "Following coloscopic diagnosis of colorectal tumors treatment was administered twice weekly for a 10-week period." | 1.27 | Comparative antitumor activity of ruthenium derivatives with 5'-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats. ( Berger, MR; Garzon, FT; Keppler, BK; Schmähl, D, 1987) |
| " 5'-DFUR was administered three or four times a day at a daily dosage of 600 to 1200 mg." | 1.27 | [Clinical phase II study of 5'-DFUR for cancer of the digestive organs by a cooperative study group]. ( Gocho, Y; Ishitani, K; Kogo, Y; Kouda, K; Koyama, R; Matsuda, M; Nagai, T; Niitsu, Y; Saijo, N; Urushizaki, I, 1985) |
| "Chemical cholecystitis has been recognized recently as a complication of hepatic artery infusion chemotherapy." | 1.27 | Hepatobiliary scintigraphy in patients receiving hepatic artery infusion chemotherapy. ( Dakhil, SR; Housholder, DF; Hynes, HE; Marymont, JV, 1985) |
| "3 microM dThd was sufficient to completely protect sensitive cells from 5-fluoro-2'-deoxyuridine, and 5,8-dideazaisofolic acid at concentrations that produced over 80% lethality in unprotected cells and the same concentration of dThd in combination with 100 microM hypoxanthine fully protected sensitive cells from greater than 99% methotrexate-induced cell lethality." | 1.27 | Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine. ( Bertino, JR; Handschumacher, RE; Sobrero, AF, 1985) |
| "Of 13 patients with hepatoma, nine had clinically significant regression with a median survival of 11 months." | 1.26 | The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol. ( Al-Sarraf, M; Baker, L; Izbicki, R; Reed, ML; Sexon-Porte, M; Singhakowinta, A; Straatsma, GW; Vaitkevicius, VK; Vaughn, CB, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 86 (38.91) | 18.7374 |
| 1990's | 68 (30.77) | 18.2507 |
| 2000's | 57 (25.79) | 29.6817 |
| 2010's | 9 (4.07) | 24.3611 |
| 2020's | 1 (0.45) | 2.80 |
| Authors | Studies |
|---|---|
| Nambaru, PK | 1 |
| Hübner, T | 1 |
| Köck, K | 1 |
| Mews, S | 1 |
| Grube, M | 1 |
| Payen, L | 1 |
| Guitton, J | 1 |
| Sendler, M | 1 |
| Jedlitschky, G | 1 |
| Rimmbach, C | 1 |
| Rosskopf, D | 1 |
| Kowalczyk, DW | 1 |
| Kroemer, HK | 1 |
| Weiss, FU | 1 |
| Mayerle, J | 1 |
| Lerch, MM | 1 |
| Ritter, CA | 1 |
| Ha, NB | 1 |
| Wang, CW | 1 |
| El-Nachef, N | 1 |
| Chang, W | 1 |
| Wei, Y | 1 |
| Ren, L | 1 |
| Zhong, Y | 2 |
| Yu, Y | 1 |
| Chen, J | 1 |
| Zhu, D | 1 |
| Ye, L | 1 |
| Qin, C | 1 |
| Zhao, N | 1 |
| Niu, W | 1 |
| Qin, X | 1 |
| Xu, J | 2 |
| Takemoto, Y | 1 |
| Noriyuki, T | 1 |
| Takei, D | 1 |
| Kawashima, M | 1 |
| Saito, R | 1 |
| Ono, N | 1 |
| Sasada, T | 1 |
| Yoshida, M | 1 |
| Yamaki, M | 1 |
| Amano, H | 1 |
| Fukuda, T | 1 |
| Nakahara, M | 1 |
| Kim, SG | 1 |
| Hwang, SH | 1 |
| Kemeny, N | 8 |
| Capanu, M | 1 |
| D'Angelica, M | 1 |
| Jarnagin, W | 2 |
| Haviland, D | 1 |
| Dematteo, R | 1 |
| Fong, Y | 3 |
| Felici, A | 1 |
| Di Segni, S | 1 |
| Milella, M | 1 |
| Colantonio, S | 1 |
| Sperduti, I | 1 |
| Nuvoli, B | 1 |
| Contestabile, M | 1 |
| Sacconi, A | 1 |
| Zaratti, M | 1 |
| Citro, G | 1 |
| Cognetti, F | 1 |
| Huh, JW | 1 |
| Kim, HR | 1 |
| Weinreich, J | 1 |
| Schott, S | 1 |
| Königsrainer, I | 1 |
| Zieker, D | 1 |
| Königsrainer, A | 1 |
| Schott, H | 1 |
| Solomon, N | 1 |
| Mezentsev, D | 2 |
| Reis, I | 1 |
| Lima, M | 2 |
| Rios, J | 2 |
| Avisar, E | 2 |
| Franceschi, D | 2 |
| Livingstone, A | 1 |
| Podolsky, L | 1 |
| Ardalan, B | 3 |
| Cohen, DJ | 1 |
| Newman, E | 2 |
| Iqbal, S | 1 |
| Chang, RY | 1 |
| Potmesil, M | 2 |
| Ryan, T | 2 |
| Donahue, B | 1 |
| Chandra, A | 1 |
| Liu, M | 1 |
| Utate, M | 1 |
| Hiotis, S | 2 |
| Pachter, LH | 1 |
| Hochster, H | 2 |
| Muggia, F | 2 |
| Bellot, GL | 1 |
| Tan, WH | 1 |
| Tay, LL | 1 |
| Koh, D | 1 |
| Wang, X | 1 |
| Wang, YY | 1 |
| Zhang, W | 1 |
| Qian, S | 1 |
| Liu, R | 1 |
| Kan, ZX | 1 |
| Wang, JH | 1 |
| Takizawa, M | 1 |
| Hirano, M | 2 |
| Murakami, N | 1 |
| Uno, Y | 1 |
| Kikuchi, T | 1 |
| Nozawa, H | 1 |
| Hara, T | 1 |
| Asaumi, Y | 1 |
| Kikkawa, H | 2 |
| Ojima, E | 1 |
| Miki, C | 1 |
| Hatada, T | 1 |
| Inoue, Y | 2 |
| Mohri, T | 1 |
| Azuma, T | 1 |
| Kusunoki, M | 1 |
| Sato, A | 2 |
| Shimada, K | 1 |
| Nakamachi, M | 1 |
| Ushio, J | 1 |
| Yamamoto, W | 1 |
| Kurihara, M | 3 |
| Matsukawa, M | 1 |
| Fujiwara, S | 1 |
| Noguchi, T | 2 |
| Suehiro, S | 1 |
| Kikuchi, R | 1 |
| Uchida, Y | 1 |
| Gonen, M | 2 |
| Stockman, J | 2 |
| Blumgart, L | 1 |
| Sperber, D | 1 |
| Hummer, A | 1 |
| HIGGINS, GA | 1 |
| WHERRY, DC | 1 |
| CLIFTON, KH | 1 |
| SZYBALSKI, W | 1 |
| HEIDELBERGER, C | 2 |
| GOLLIN, FF | 1 |
| ANSFIELD, FJ | 2 |
| VERMUND, H | 1 |
| OETTGEN, HF | 1 |
| CLIFFORD, P | 1 |
| CANDLER, P | 1 |
| THIELE, EH | 1 |
| ARISON, RN | 1 |
| BOXER, GE | 1 |
| SHERLOCK, P | 1 |
| SULLIVAN, RD | 1 |
| WATKINS, E | 1 |
| BOOHAR, J | 1 |
| WILSON, WL | 1 |
| DELAGARZA, JG | 1 |
| Maruyama, S | 1 |
| Tamiya, Y | 1 |
| Nihei, K | 1 |
| Kitami, C | 1 |
| Kato, T | 1 |
| Kikkawa, N | 3 |
| Tsujie, M | 1 |
| Iijima, S | 1 |
| Handa, R | 1 |
| Naoi, Y | 1 |
| Oshima, S | 1 |
| Yamamoto, H | 2 |
| Kurokawa, E | 1 |
| Ichikawa, J | 1 |
| Koizumi, W | 2 |
| Tanabe, S | 1 |
| Takeuchi, H | 1 |
| Nagaba, S | 1 |
| Higuchi, K | 1 |
| Sasaki, T | 1 |
| Tahara, K | 1 |
| Murakami, S | 1 |
| Kitamura, T | 1 |
| Nakai, H | 1 |
| Saigenji, K | 1 |
| Haraguchi, Y | 1 |
| Shimizu, H | 1 |
| Takahashi, M | 3 |
| Nakano, M | 1 |
| Okusawa, A | 1 |
| Suzuki, M | 3 |
| Hikino, H | 1 |
| Yamada, T | 2 |
| Hata, T | 1 |
| Nakamura, K | 2 |
| Sugimoto, S | 1 |
| Kanazawa, A | 1 |
| Tokuka, A | 1 |
| Ozaki, N | 1 |
| Nagaoka, S | 1 |
| Zhang, JM | 1 |
| Liu, MJ | 1 |
| Mizoi, T | 1 |
| Shiiba, K | 1 |
| Sasak, I | 1 |
| Matsuno, S | 1 |
| Patel, M | 1 |
| Agarwal, R | 1 |
| Nakazaki, T | 1 |
| Shibata, K | 1 |
| Haseba, M | 1 |
| Taniguchi, H | 1 |
| Nakao, S | 1 |
| Takahara, O | 1 |
| Otvös, L | 1 |
| Sági, G | 1 |
| Yoshitani, S | 1 |
| Imaizumi, H | 1 |
| Kuroda, M | 1 |
| Yokoi, M | 1 |
| Tanaka, Y | 6 |
| Harada, H | 1 |
| Kosaka, T | 1 |
| Takashima, S | 1 |
| Tamesa, T | 1 |
| Watanabe, Y | 1 |
| Yoshimura, K | 1 |
| Mori, N | 1 |
| Yamamoto, S | 2 |
| Hazama, S | 1 |
| Tangoku, A | 1 |
| Oka, M | 1 |
| Phongkitkarun, S | 1 |
| Kobayashi, S | 1 |
| Varavithya, V | 1 |
| Huang, X | 1 |
| Curley, SA | 1 |
| Charnsangavej, C | 2 |
| Sawada, T | 1 |
| Nishimura, M | 1 |
| Hirose, K | 1 |
| Marcus, S | 1 |
| Yee, H | 1 |
| Norwood, B | 1 |
| Wendell, M | 1 |
| Suzuki, S | 1 |
| Sekikawa, K | 2 |
| Fujita, S | 1 |
| Abe, N | 1 |
| Ishigame, T | 1 |
| Okada, R | 1 |
| Gonda, K | 1 |
| Saito, M | 1 |
| Onogi, H | 1 |
| Ohki, S | 1 |
| Takenoshita, S | 1 |
| Zhao, WH | 1 |
| Wang, SF | 1 |
| Ding, W | 1 |
| Sheng, JM | 1 |
| Ma, ZM | 1 |
| Teng, LS | 1 |
| Wang, M | 1 |
| Wu, FS | 1 |
| Luo, B | 1 |
| Kuwakado, S | 1 |
| Takiuchi, H | 3 |
| Goto, M | 3 |
| Kawabe, S | 1 |
| Ohta, S | 1 |
| Kii, T | 1 |
| Tanaka, T | 4 |
| Nishitani, H | 1 |
| Katsu, K | 2 |
| Brenner, B | 1 |
| Shah, MA | 1 |
| Karpeh, MS | 1 |
| Brennan, MF | 2 |
| Coit, DG | 1 |
| Klimstra, DS | 1 |
| Tang, LH | 1 |
| Kelsen, DP | 2 |
| Gotoh, J | 1 |
| Akabane, H | 1 |
| Kita, K | 1 |
| Fujiyoshi, M | 1 |
| Hirokata, G | 1 |
| Imai, K | 1 |
| Kawai, T | 1 |
| Yanagida, N | 1 |
| Nakano, S | 1 |
| Ryan, DP | 1 |
| Nakamura, Y | 2 |
| Nagao, J | 1 |
| Saida, Y | 1 |
| Enomoto, T | 1 |
| Katagiri, M | 1 |
| Nagao, S | 1 |
| Watanabe, M | 1 |
| Kusachi, S | 1 |
| Sumiyama, Y | 1 |
| Nozawa, K | 1 |
| Oomi, T | 1 |
| Aoyagi, Y | 1 |
| Hayama, T | 1 |
| Yamada, H | 2 |
| Haku, K | 1 |
| Matsuda, K | 1 |
| Mimura, T | 1 |
| Watanabe, T | 2 |
| Wada, Y | 1 |
| Kikuchi, K | 1 |
| Takahashi, W | 1 |
| Honda, J | 1 |
| Nakanishi, J | 1 |
| Matsumoto, K | 1 |
| Kuwahara, T | 1 |
| Kai, N | 1 |
| Kikukawa, H | 1 |
| Ueda, S | 1 |
| Weixin, N | 1 |
| Xinyu, Q | 1 |
| Yanhan, L | 1 |
| Li, R | 1 |
| Jianhua, W | 1 |
| Zhiping, Y | 1 |
| Jiemin, C | 1 |
| Spector, SA | 1 |
| Livingstone, AS | 1 |
| Bowen-Wells, CP | 1 |
| Sparling, L | 1 |
| Sapp, M | 1 |
| Walker, G | 1 |
| Ganjei-Azar, P | 1 |
| Ishizu, K | 1 |
| Sunose, N | 1 |
| Yamazaki, K | 1 |
| Tsuruo, T | 1 |
| Sadahiro, S | 1 |
| Makuuchi, H | 1 |
| Yamori, T | 2 |
| Kim, H | 1 |
| Park, JH | 1 |
| Shin, SJ | 1 |
| Kim, MJ | 1 |
| Bang, SJ | 1 |
| Park, NH | 1 |
| Nah, YW | 1 |
| Nam, CW | 1 |
| Joo, KR | 1 |
| Min, YJ | 1 |
| Imamura, H | 1 |
| Furukawa, H | 2 |
| Imano, M | 1 |
| Imamoto, H | 1 |
| Kimura, Y | 1 |
| Ishida, H | 2 |
| Fujitani, K | 1 |
| Narahara, H | 1 |
| Shimokawa, T | 1 |
| Crowley, ML | 1 |
| Patt, YZ | 2 |
| Peters, RE | 1 |
| Chuang, VP | 1 |
| Wallace, S | 3 |
| Mavligit, G | 1 |
| Oberfield, RA | 3 |
| Abele, R | 1 |
| Alberto, P | 2 |
| Kaplan, S | 2 |
| Siegenthaler, P | 1 |
| Hofmann, V | 1 |
| Ryssel, HJ | 1 |
| Hartmann, D | 1 |
| Holdener, EE | 1 |
| Cavalli, F | 2 |
| Daly, J | 2 |
| Oderman, P | 4 |
| Shike, M | 1 |
| Chun, H | 1 |
| Petroni, G | 1 |
| Geller, N | 2 |
| Fujita, F | 1 |
| Fujita, M | 1 |
| Taguchi, T | 1 |
| Reed, ML | 1 |
| Vaitkevicius, VK | 1 |
| Al-Sarraf, M | 1 |
| Vaughn, CB | 1 |
| Singhakowinta, A | 1 |
| Sexon-Porte, M | 1 |
| Izbicki, R | 1 |
| Baker, L | 1 |
| Straatsma, GW | 1 |
| Houghton, JA | 2 |
| Houghton, PJ | 2 |
| Bronstein, BR | 1 |
| Steele, GD | 1 |
| Ensminger, W | 1 |
| Kaplan, WD | 1 |
| Lowenstein, MS | 1 |
| Wilson, RE | 1 |
| Forman, J | 1 |
| Zamcheck, N | 1 |
| Hall, DA | 1 |
| Clouse, ME | 2 |
| Gramm, HF | 1 |
| Tilchen, E | 1 |
| McBride, CM | 1 |
| Chuang, V | 1 |
| Mavligit, CM | 1 |
| Arisawa, Y | 1 |
| Sutanto-Ward, E | 1 |
| Fortunato, L | 1 |
| Sigurdson, ER | 2 |
| Inaba, M | 1 |
| Sato, S | 1 |
| Yoshimura, M | 1 |
| Ohnishi, Y | 1 |
| Tashiro, T | 1 |
| Murakami, H | 1 |
| Adachi, H | 1 |
| Kurihara, T | 1 |
| Tamura, Y | 2 |
| Kobori, O | 1 |
| Saito, K | 1 |
| Ishihata, R | 2 |
| Kuwana, T | 1 |
| Obara, K | 1 |
| Nishimaki, T | 1 |
| Kasukawa, R | 1 |
| Ng, B | 1 |
| Lenert, JT | 1 |
| Weksler, B | 1 |
| Port, JL | 1 |
| Ellis, JL | 1 |
| Burt, ME | 1 |
| Fujimoto, T | 1 |
| Takami, M | 1 |
| Okumura, Y | 1 |
| Takada, T | 1 |
| Kitada, M | 1 |
| Tsukahara, Y | 1 |
| Shibata, T | 1 |
| Murotani, M | 1 |
| Iihara, K | 1 |
| Niiyama, H | 2 |
| Yoshida, J | 2 |
| Matoba, N | 2 |
| Nagata, T | 3 |
| Kobayashi, J | 1 |
| Kubota, K | 1 |
| Ishikawa, H | 2 |
| Asaumi, S | 1 |
| Iwanami, K | 1 |
| Matsumoto, H | 1 |
| Kawashima, K | 1 |
| Yokoe, T | 1 |
| Iino, Y | 1 |
| Morishita, Y | 1 |
| Tajima, H | 1 |
| Matsuki, N | 1 |
| Takeda, T | 1 |
| Horichi, H | 1 |
| Kumaki, T | 1 |
| Shima, K | 1 |
| Etoh, T | 2 |
| Maeda, Y | 1 |
| Kemeny, MM | 1 |
| Alava, G | 1 |
| Oliver, JM | 1 |
| Watanabe, K | 1 |
| Igarashi, T | 1 |
| Hayashi, T | 1 |
| Yoshida, K | 2 |
| Hanyu, F | 1 |
| Kodama, I | 1 |
| Aoyagi, K | 1 |
| Kumegawa, H | 1 |
| Ohta, J | 1 |
| Maruiwa, M | 1 |
| Kofuji, K | 1 |
| Takeda, J | 1 |
| Kakegawa, T | 1 |
| Sasai, T | 1 |
| Yoshida, S | 1 |
| Morise, K | 1 |
| Imamura, A | 1 |
| Akazawa, S | 1 |
| Betsuyaku, T | 1 |
| Ohkubo, S | 1 |
| Takahashi, H | 1 |
| Tsumura, I | 2 |
| Tsuji, K | 1 |
| Hori, K | 1 |
| Kimura, S | 1 |
| Takagaki, M | 1 |
| Koumoto, T | 1 |
| Andou, T | 1 |
| Iwagaki, H | 1 |
| Hizuta, A | 1 |
| Fujiwara, T | 1 |
| Perdomo, JA | 1 |
| Tanaka, N | 1 |
| Orita, K | 1 |
| Kameyama, M | 1 |
| Nakamori, S | 1 |
| Imaoka, S | 1 |
| Yasuda, T | 1 |
| Ohigashi, H | 1 |
| Hiratsuka, M | 1 |
| Sasaki, Y | 1 |
| Kabuto, T | 1 |
| Ishikawa, O | 1 |
| Iwanaga, T | 1 |
| Yokouchi, H | 1 |
| Doi, O | 1 |
| Crookes, P | 1 |
| Leichman, CG | 2 |
| Leichman, L | 2 |
| Tan, M | 1 |
| Laine, L | 2 |
| Stain, S | 2 |
| Baranda, J | 1 |
| Casagrande, Y | 1 |
| Groshen, S | 1 |
| Silberman, H | 2 |
| Tazawa, K | 1 |
| Sakamoto, T | 1 |
| Kuroki, Y | 1 |
| Yamashita, I | 1 |
| Okamoto, M | 1 |
| Katuyama, S | 1 |
| Fujimaki, M | 1 |
| Tomoda, H | 1 |
| Morita, M | 1 |
| Matsuoka, H | 1 |
| Baba, H | 1 |
| Taketomi, A | 1 |
| Kohnoe, S | 1 |
| Seo, Y | 1 |
| Saito, T | 1 |
| Tomita, H | 1 |
| Fukunari, H | 1 |
| Shibata, M | 1 |
| Iwasaki, A | 1 |
| Sanada, K | 1 |
| Enomoto, M | 1 |
| Ichikawa, W | 1 |
| Kitago, K | 1 |
| Nihei, Z | 1 |
| Yamada, Y | 1 |
| Miyagawa, T | 1 |
| Toyoda, H | 1 |
| Uesato, K | 1 |
| Asanuma, F | 1 |
| Takita, M | 1 |
| Onda, M | 1 |
| Tokunaga, A | 1 |
| Shirakawa, T | 1 |
| Ikeda, K | 1 |
| Hiramoto, Y | 1 |
| Teramoto, T | 1 |
| Oguri, T | 1 |
| Fujita, I | 1 |
| Okuda, T | 1 |
| Mizutani, T | 1 |
| Kiyama, T | 1 |
| Yoshiyuki, T | 1 |
| Matsukura, N | 1 |
| Kan, K | 1 |
| Naitoh, K | 1 |
| Tsuruta, A | 1 |
| Mizuta, N | 1 |
| Ohmori, K | 1 |
| Kawachi, H | 1 |
| Amaike, H | 1 |
| Yanada, M | 1 |
| Ohmori, Y | 1 |
| Okamura, A | 1 |
| Ohmura, Y | 1 |
| Islam, MM | 1 |
| Tagawa, M | 1 |
| Horitsu, K | 1 |
| Moriyama, Y | 1 |
| Fujimura, S | 1 |
| Kojima, Y | 1 |
| Ito, K | 1 |
| Takano, M | 1 |
| Akatsuka, H | 1 |
| Sato, Y | 1 |
| Igari, H | 1 |
| Nakagawa, H | 1 |
| Yamada, M | 1 |
| Maeda, N | 1 |
| Iwatsuki, K | 1 |
| Tsuzuki, T | 1 |
| Hirayama, A | 1 |
| Ikenaka, K | 1 |
| Mavligit, GM | 1 |
| Estrov, Z | 1 |
| Ayala, A | 1 |
| Honda, M | 1 |
| Matsuo, Y | 1 |
| Hazama, K | 1 |
| Takao, T | 1 |
| Fushimi, H | 1 |
| Ohtani, Y | 1 |
| Aihara, S | 1 |
| Kanazawa, H | 1 |
| Hiki, Y | 1 |
| Kakita, A | 1 |
| Gotoh, M | 1 |
| Hirata, I | 1 |
| Iyama, M | 1 |
| Inoue, R | 1 |
| Itabashi, T | 1 |
| Egashira, Y | 1 |
| Inoue, T | 1 |
| Kurisu, Y | 1 |
| Tanaka, M | 1 |
| Shimamoto, C | 1 |
| Kornmann, M | 1 |
| Danenberg, KD | 1 |
| Arber, N | 1 |
| Beger, HG | 1 |
| Danenberg, PV | 1 |
| Korc, M | 1 |
| Evrard, A | 1 |
| Cuq, P | 1 |
| Ciccolini, J | 1 |
| Vian, L | 1 |
| Cano, JP | 1 |
| Matsumoto, S | 1 |
| Mashiba, H | 1 |
| Okamoto, K | 1 |
| Ekimoto, H | 1 |
| Kiyono, T | 1 |
| Nishiwaki, M | 1 |
| Okuda, K | 1 |
| Tsujitsuka, K | 1 |
| Kano, Y | 1 |
| Koga, T | 1 |
| Ishimaru, K | 1 |
| Goto, T | 1 |
| Sumiyama, M | 1 |
| Huang, Y | 1 |
| Cohen, AM | 2 |
| Shi, W | 1 |
| Conti, JA | 1 |
| Bertino, JR | 5 |
| Turnbull, AD | 1 |
| Sullivan, D | 1 |
| Blumgart, LH | 1 |
| Thirion, P | 1 |
| Wolmark, N | 1 |
| Haddad, E | 1 |
| Buyse, M | 1 |
| Piedbois, P | 1 |
| Lorenz, M | 3 |
| Müller, HH | 2 |
| Musha, N | 1 |
| Sunami, E | 1 |
| Sasaki, M | 1 |
| Saito, H | 2 |
| Sando, N | 1 |
| Setu, Y | 1 |
| Setu, M | 1 |
| Oka, K | 1 |
| Takeuchi, I | 1 |
| Suzuki, T | 1 |
| Nakada, H | 1 |
| Idezuki, Y | 1 |
| Hohya, I | 1 |
| Atkins, CD | 1 |
| Venook, AP | 1 |
| Althaus, B | 1 |
| Warren, RS | 1 |
| Hochmuth, K | 1 |
| Fata, F | 1 |
| Ron, IG | 1 |
| Maluf, F | 1 |
| Klimstra, D | 1 |
| Hussey, HJ | 1 |
| Todorov, PT | 1 |
| Field, WN | 1 |
| Inagaki, N | 1 |
| Ishitsuka, H | 4 |
| Tisdale, MJ | 1 |
| Delauter, BJ | 1 |
| Ramanathan, RK | 1 |
| Egorin, MJ | 1 |
| Stover, LL | 1 |
| Zuhowski, EG | 1 |
| Plunkett, W | 1 |
| Zamboni, WC | 1 |
| Min, JS | 2 |
| Kim, NK | 2 |
| Park, JK | 1 |
| Yun, SH | 1 |
| Noh, JK | 1 |
| Sumimoto, R | 1 |
| Ichiba, Y | 1 |
| Emoto, K | 1 |
| Imaoka, Y | 1 |
| Ishizaki, Y | 1 |
| Tokumoto, N | 1 |
| Seong, J | 1 |
| Cho, JH | 1 |
| Suh, CO | 1 |
| Sawabe, M | 1 |
| Arai, T | 1 |
| Esaki, Y | 1 |
| Tsuru, M | 1 |
| Fukazawa, T | 1 |
| Takubo, K | 1 |
| Lowy, AM | 1 |
| Culliford, AT | 1 |
| Brooks, AD | 1 |
| Sharma, S | 1 |
| Saltz, LB | 1 |
| Schwartz, GK | 1 |
| O'Reilly, EM | 1 |
| Ilson, DH | 1 |
| Kemeny, NE | 2 |
| Guillem, JG | 1 |
| Wong, WD | 1 |
| Paty, PB | 1 |
| Gray, B | 1 |
| Van Hazel, G | 1 |
| Hope, M | 1 |
| Burton, M | 1 |
| Moroz, P | 1 |
| Anderson, J | 1 |
| Gebski, V | 1 |
| Wagman, LD | 1 |
| Litvak, DA | 1 |
| Wood, TF | 1 |
| Tsioulias, GJ | 1 |
| Chung, M | 1 |
| Chawla, SP | 1 |
| Foshag, LJ | 1 |
| Morton, DL | 1 |
| Ramming, KP | 1 |
| Bilchik, AJ | 1 |
| Nakamori, M | 1 |
| Iwahashi, M | 1 |
| Yamaue, H | 1 |
| Ogawa, M | 1 |
| Takao, Y | 1 |
| Mukai, H | 1 |
| Satou, K | 1 |
| Anazawa, S | 1 |
| Yamazaki, Y | 1 |
| Aoki, T | 1 |
| Bozzetti, F | 1 |
| Andreola, S | 1 |
| Baratti, D | 1 |
| Mariani, L | 1 |
| Stani, SC | 1 |
| Valvo, F | 1 |
| Spinelli, P | 1 |
| Carter, SK | 2 |
| Wasserman, TH | 1 |
| Fritze, D | 1 |
| Kern, DH | 1 |
| Drogemuller, CR | 1 |
| Pilch, YH | 1 |
| McCaffrey, JA | 1 |
| Polio, J | 1 |
| Hamilton, T | 1 |
| Sugimoto, Y | 1 |
| Ohe, Y | 1 |
| Nishio, K | 1 |
| Ohmori, T | 1 |
| Fujiwara, Y | 1 |
| Saijo, N | 2 |
| Hashimoto, T | 1 |
| Araki, H | 1 |
| Yoshioka, T | 1 |
| Yasui, K | 1 |
| Kodama, M | 1 |
| Kurimoto, N | 1 |
| Yasuzawa, Y | 1 |
| Itoh, N | 1 |
| Tamura, T | 1 |
| Yoshimoto, I | 1 |
| Kiyasu, Y | 1 |
| Kashu, Y | 1 |
| Sakai, K | 1 |
| Shigematsu, S | 1 |
| Furuya, K | 1 |
| Moriuchi, A | 1 |
| Satoh, H | 1 |
| Iigo, M | 6 |
| Nishikata, K | 3 |
| Hoshi, A | 4 |
| Daemen, T | 2 |
| Regts, J | 1 |
| Morselt, H | 1 |
| Scherphof, GL | 2 |
| Kato, M | 1 |
| Sawai, K | 1 |
| Noguchi, A | 1 |
| Minato, H | 1 |
| Takahashi, T | 1 |
| Spears, CP | 1 |
| Ray, M | 1 |
| Muggia, FM | 1 |
| Kiyabu, M | 1 |
| Radin, R | 1 |
| Marsh, JC | 1 |
| Durivage, HJ | 1 |
| Davis, C | 1 |
| O'Hollaren, K | 1 |
| Pasquale, DN | 1 |
| Simonich, SA | 1 |
| Voynick, IM | 1 |
| Noda, K | 1 |
| Ikeda, M | 1 |
| Saito, Y | 1 |
| Yajima, A | 1 |
| Terashima, Y | 1 |
| Ochiai, K | 1 |
| Takada, M | 1 |
| Eda, H | 2 |
| Fujimoto, K | 1 |
| Ishikawa, T | 2 |
| Yoshinaka, K | 1 |
| Yagi, M | 1 |
| Ohtagaki, S | 1 |
| Toi, M | 1 |
| Toge, T | 1 |
| Yin, MB | 1 |
| Rustum, YM | 1 |
| Maeda, H | 1 |
| Miyamoto, T | 1 |
| Mochinaga, N | 1 |
| Tsunoda, T | 1 |
| Kahky, MP | 1 |
| Lind, DS | 1 |
| Cruz, AB | 1 |
| Gaskill, HV | 1 |
| Kubota, Y | 1 |
| Miura, T | 1 |
| Shuin, T | 1 |
| Kinoshita, Y | 1 |
| Hosaka, M | 1 |
| Kondo, I | 1 |
| Moriyama, M | 1 |
| Fukushima, S | 1 |
| Fukuoka, H | 1 |
| Miyai, K | 1 |
| Tsuchiya, Y | 1 |
| Kobayakawa, K | 1 |
| Kawahara, T | 1 |
| von Roemeling, R | 1 |
| Hrushesky, WJ | 1 |
| Nakajima, Y | 4 |
| Szinai, I | 1 |
| Veres, Z | 1 |
| Szabolcs, A | 1 |
| De Clercq, E | 3 |
| Sakatoku, M | 1 |
| Matsu, T | 1 |
| Harada, T | 1 |
| Tatsuzawa, T | 1 |
| Masuda, S | 1 |
| Matherly, LH | 1 |
| Czajkowski, CA | 1 |
| Muench, SP | 1 |
| Psiakis, JT | 1 |
| Williams, LG | 1 |
| de Graaf, SS | 1 |
| Cheshire, PJ | 1 |
| Rodman, JH | 1 |
| Maneval, DC | 1 |
| Wainer, IW | 1 |
| Jadaud, P | 1 |
| Hiromoto, M | 1 |
| Yasui, A | 1 |
| Nishida, Y | 1 |
| Kumagai, K | 1 |
| Sanada, Y | 1 |
| Masuo, K | 1 |
| Kobayashi, K | 1 |
| Nakayama, A | 1 |
| Miwa, M | 1 |
| Martin, JK | 1 |
| O'Connell, MJ | 1 |
| Wieand, HS | 1 |
| Fitzgibbons, RJ | 1 |
| Mailliard, JA | 1 |
| Rubin, J | 1 |
| Nagorney, DM | 1 |
| Tschetter, LK | 1 |
| Krook, JE | 1 |
| Kernstine, KH | 1 |
| Kryjeski, SR | 1 |
| Hall, LJ | 1 |
| Larson, RE | 1 |
| Saylor, HL | 1 |
| Fortuny, IE | 1 |
| Nakaguchi, K | 1 |
| Nakano, Y | 1 |
| Kitahara, T | 1 |
| Onoe, K | 1 |
| Nagamine, H | 1 |
| Fukuda, H | 1 |
| Watanabe, S | 1 |
| Mayama, M | 1 |
| Oguro, M | 1 |
| Wakatsuki, S | 1 |
| Majima, H | 1 |
| Tsai, CM | 1 |
| Gazdar, AF | 1 |
| Allegra, C | 1 |
| Perng, RP | 1 |
| Kramer, BS | 1 |
| Lönn, U | 3 |
| Lönn, S | 3 |
| Elias, L | 1 |
| Crissman, HA | 1 |
| Yamaizumi, Z | 1 |
| Nishimura, S | 1 |
| Niedzwiecki, D | 1 |
| Shurgot, B | 1 |
| Nylen, U | 1 |
| Winblad, G | 1 |
| Araki, E | 1 |
| Sakata, Y | 1 |
| Ogasawara, H | 1 |
| Itoh, T | 1 |
| Furukohri, N | 1 |
| Saitoh, S | 1 |
| Tsushima, K | 1 |
| Baba, T | 1 |
| Munakata, A | 1 |
| Yoshida, Y | 1 |
| Safi, F | 1 |
| Bittner, R | 1 |
| Roscher, R | 1 |
| Schuhmacher, K | 1 |
| Gaus, W | 1 |
| Beger, GH | 1 |
| Okudaira, N | 1 |
| Odagiri, H | 1 |
| Zanea-Wangler, E | 1 |
| Schmitz, R | 1 |
| Kesseler, J | 1 |
| Ploss, HJ | 1 |
| Sobrero, A | 1 |
| Romanini, A | 1 |
| Russello, O | 1 |
| Nicolin, A | 1 |
| Rosso, R | 1 |
| Rougier, P | 2 |
| Lasser, P | 2 |
| Elias, D | 2 |
| Ghosn, M | 2 |
| Ducreux, M | 2 |
| Lumbroso, J | 2 |
| Sidibe, S | 2 |
| Droz, JP | 2 |
| Ohkawa, T | 1 |
| Matsuda, M | 2 |
| Nagao, K | 1 |
| Baba, K | 1 |
| Nishimura, R | 1 |
| Matsuoka, Y | 1 |
| Ueno, Y | 1 |
| Morinaga, H | 1 |
| Nagase, H | 1 |
| Kawano, H | 1 |
| Ueda, M | 1 |
| Misaki, O | 1 |
| Okamoto, Y | 1 |
| Maeda, T | 1 |
| Okamura, S | 1 |
| Ueki, M | 1 |
| Sugimoto, O | 1 |
| Schuster, D | 1 |
| Heim, ME | 1 |
| Decoster, G | 1 |
| Queisser, W | 1 |
| Hottenrott, C | 1 |
| Inglis, R | 1 |
| Kirkowa-Reimann, M | 1 |
| Seeger, J | 1 |
| Woodcock, TM | 1 |
| Blumenreich, MS | 1 |
| Richardson, JD | 1 |
| Carrasco, CH | 1 |
| Richli, W | 1 |
| Haynie, TP | 1 |
| Drings, P | 1 |
| Calcanis, A | 1 |
| Komuro, K | 1 |
| Mitsumori, N | 1 |
| Iwamoto, K | 1 |
| Murai, R | 1 |
| Ishida, T | 1 |
| Nagasaki, Y | 1 |
| Hujii, Y | 1 |
| Amano, R | 1 |
| Yamazaki, M | 1 |
| Nagayama, A | 1 |
| Lafon, PC | 1 |
| Reed, K | 1 |
| Rosenthal, D | 1 |
| Laughlin, EH | 1 |
| Simoni, G | 1 |
| Bignami, P | 1 |
| Civalleri, D | 1 |
| Cosimelli, M | 1 |
| Craus, W | 1 |
| Percivale, PL | 1 |
| Repetto, M | 1 |
| Holl, E | 1 |
| Zänker, KS | 1 |
| Lange, J | 1 |
| Siewert, JR | 1 |
| Ridge, JA | 1 |
| Daly, JM | 2 |
| Taylor, HG | 1 |
| Wolf, CR | 1 |
| Maitland, CG | 1 |
| Malet-Martino, MC | 2 |
| Faure, F | 1 |
| Vialaneix, JP | 1 |
| Palevody, C | 1 |
| Hollande, E | 1 |
| Martino, R | 2 |
| Anderson, SD | 1 |
| Holley, HC | 1 |
| Berland, LL | 1 |
| Van Dyke, JA | 1 |
| Stanley, RJ | 1 |
| Fosså, SD | 1 |
| Flokkmann, A | 1 |
| Heier, M | 1 |
| Aas, M | 1 |
| Moe, B | 1 |
| Heintz, R | 1 |
| Linder-Ciccolunghi, S | 1 |
| Siegel, JH | 1 |
| Ramsey, WH | 1 |
| Dikengil, A | 1 |
| Siskind, BN | 1 |
| Morse, SS | 1 |
| Swedlund, A | 1 |
| Bober-Sorcinelli, KE | 1 |
| Burrell, MI | 1 |
| Reichman, BS | 1 |
| Yeh, SD | 1 |
| Garzon, FT | 1 |
| Berger, MR | 1 |
| Keppler, BK | 1 |
| Schmähl, D | 1 |
| Bernadou, J | 1 |
| Roché, H | 1 |
| Armand, JP | 1 |
| Reichman, B | 1 |
| Botet, J | 1 |
| Kassirer, JP | 1 |
| Kopelman, RI | 1 |
| Sigurdson, E | 1 |
| Thom, A | 1 |
| Monk, MR | 1 |
| Sanchez, JD | 1 |
| Phelps, CD | 1 |
| Miller, DM | 1 |
| Spanjer, HH | 1 |
| Roerdink, FH | 1 |
| Mermillod, B | 1 |
| Germano, G | 1 |
| Weber, W | 1 |
| Joss, R | 1 |
| Spati, B | 1 |
| Martz, G | 1 |
| Hutchins, LF | 1 |
| Webb, RT | 1 |
| Ortego, TJ | 1 |
| Lang, NP | 1 |
| Navab, F | 1 |
| Urushizaki, I | 1 |
| Kogo, Y | 1 |
| Kouda, K | 1 |
| Ishitani, K | 1 |
| Niitsu, Y | 1 |
| Gocho, Y | 1 |
| Koyama, R | 1 |
| Nagai, T | 1 |
| Shepard, KV | 1 |
| Levin, B | 1 |
| Karl, RC | 1 |
| Faintuch, J | 1 |
| DuBrow, RA | 1 |
| Hagle, M | 1 |
| Cooper, RM | 1 |
| Beschorner, J | 1 |
| Stablein, D | 1 |
| Housholder, DF | 1 |
| Hynes, HE | 1 |
| Dakhil, SR | 1 |
| Marymont, JV | 1 |
| Suzuki, H | 1 |
| Sobrero, AF | 2 |
| Moir, RD | 1 |
| Handschumacher, RE | 2 |
| Pien, EH | 1 |
| Zeman, RK | 1 |
| Benjamin, SB | 1 |
| Barth, KH | 1 |
| Jaffe, MH | 1 |
| Choyke, PL | 1 |
| Clark, LR | 1 |
| Paushter, DM | 1 |
| Pettavel, J | 1 |
| Morgenthaler, F | 1 |
| Nishizawa, Y | 1 |
| Casida, JE | 1 |
| Burrows, JH | 1 |
| Talley, RW | 1 |
| Drake, EH | 1 |
| Tucker, WG | 1 |
| Dendy, PP | 1 |
| Serlin, O | 1 |
| Wolkoff, JS | 1 |
| Amadeo, JM | 1 |
| Keehn, RJ | 1 |
| Moertel, CG | 1 |
| Reitemeier, RJ | 1 |
| Schutt, AJ | 1 |
| Hahn, RG | 1 |
| Jato, J | 1 |
| Windheuser, JJ | 1 |
| Davis, HL | 1 |
| Ramirez, G | 1 |
| Selawry, OS | 1 |
| Comis, RL | 1 |
| Van Dyk, JJ | 1 |
| Clarkson, BD | 1 |
| Duschinsky, R | 1 |
| Keller, O | 1 |
| La Sala, E | 1 |
| Krakoff, IH | 1 |
| Morrow, LB | 1 |
| Burrow, GN | 1 |
| Kaplan, SR | 1 |
| Mulrow, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection.[NCT01972503] | Phase 4 | 300 participants (Anticipated) | Interventional | 2008-06-30 | Recruiting | ||
| A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin In Patients With Unresectable Hepatic Metastases From Colorectal Cancer[NCT00008294] | Phase 1 | 0 participants | Interventional | 2000-08-31 | Completed | ||
| A Nonrandomized Phase II Study: Feasibility and Outcome of Neo Adjuvant Chemotherapy With Oxaliplatin, Fluorodeoxyuridine (FUdR), Taxotere and Leucovorin in the Treatment of Previously Untreated Advanced Esophago-Gastric Carcinoma[NCT00448760] | Phase 2 | 29 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Phase II Study of Systemic Therapy With CPT-11 (Camptosar HCl) and Cisplatin in Patients With Advanced Gastric Cancer to be Followed by Surgical Resection and Postoperative Intraperitoneal Chemotherapy[NCT00004103] | Phase 2 | 0 participants | Interventional | 1998-07-31 | Completed | ||
| A Humanitarian Device Exemption Use Protocol of Therasphere® for Treatment of Unresectable Hepatocellular and Metastatic Liver Tumors - HDE #980006[NCT00701168] | 0 participants | Expanded Access | No longer available | ||||
| Short-term Effects of Laparoscopic-assisted Small-incision Surgery Versus Conventional Laparotomy in Treatment of Resectable Colorectal Liver Metastasis[NCT02350166] | Phase 3 | 40 participants (Anticipated) | Interventional | 2013-11-30 | Recruiting | ||
| A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer[NCT00001428] | Phase 2 | 65 participants | Interventional | 1995-02-28 | Completed | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Overall response = Complete response (CR) + Partial Response (PR). Evaluated via endoscopic ultrasounds, PET and CT scans of the chest:~Complete Response (CR) applies to participants complete disappearance of all measurable and evaluable disease. No new lesion. No disease related symptoms. No evidence of non-evaluable disease, including tumor markers and other laboratory values.~Partial Response (PR) applies to participants with at least 50 percent reduction in the sum of the products of bi-dimensional perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions." (NCT00448760)
Timeframe: 8 - 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Single Arm | 72.4 |
(NCT00448760)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Single Arm | 13.6 |
(NCT00448760)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Single Arm | 21.4 |
No evidence of cellular residual cancerous cells as evidenced by tumor tissue samples taken via surgery at the end of neo-adjuvant chemotherapy. (NCT00448760)
Timeframe: 8 - 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Single Arm | 16.7 |
6 reviews available for floxuridine and Adenocarcinoma
| Article | Year |
|---|---|
[A case of 10-year survival after combination chemotherapy of 5'-deoxy-5-fluorouridine and cisplatin and adjuvant surgery for gastric cancer with liver metastasis].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality | 2004 |
Nonsurgical approaches to colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Che | 2006 |
[Peritoneal dissemination of cecal cancer disappearing in a patient taking 5'-DFUR for 3 years].
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Cecal Neoplasms; Female; Floxuridine; Humans; Middle Ag | 1994 |
Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1999 |
Monochemotherapy of bronchogenic carcinoma withs special reference to cell type.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Carcinoma, Bronchogenic; Cytarabine; Dacti | 1973 |
A review of chemotherapy in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carmustine; Chlorambucil; Chromomycins; Cyclophosphamide; Cyt | 1974 |
35 trials available for floxuridine and Adenocarcinoma
| Article | Year |
|---|---|
Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chem | 2016 |
Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2009 |
A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2011 |
Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2003 |
Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2005 |
Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2006 |
A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2006 |
Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Pro | 2008 |
Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Neoadjuvant, surgery and adjuvant chemotherapy without radiation for esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2007 |
Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D | 2008 |
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free | 2008 |
A phase II study of combination therapy with 5'-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1993 |
Effect of low dose cyclophosphamide on the synthesis of acute phase protein and its significance for cancer chemotherapy.
Topics: Acute-Phase Proteins; Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemothera | 1996 |
Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1997 |
[Effect of CDDP/5'-DFUR combination chemotherapy for advanced or recurrent gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chil | 1998 |
[Clinical application of FdUrd to meningeal dissemination of malignant tumors].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Drug Admin | 1998 |
[Antitumor effect of 5'-DFUR and PyNPase activity in colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Admini | 1999 |
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 1999 |
Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2000 |
A prospective randomized trial comparing intravenous 5-fluorouracil and oral doxifluridine as postoperative adjuvant treatment for advanced rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disea | 2000 |
Preoperative chemoradiotherapy with oral doxifluridine plus low-dose oral leucovorin in unresectable primary rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2001 |
Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Di | 2001 |
Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; California; Camptothecin; Colorectal | 2002 |
Preoperative chemoradiation in patients with resectable rectal cancer: results on tumor response.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2002 |
Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1992 |
Phase II study of pulse 5-fluoro-2'-deoxyuridine and leucovorin in advanced colorectal cancer patients previously treated with chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Adm | 1992 |
Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial.
Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusion Pump | 1990 |
Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Results of a controlled clinical trial.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fl | 1989 |
Prevention of extrahepatic disease during intraarterial floxuridine of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment? A prospective multicenter study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Inju | 1989 |
Phase I/II tolerability/pharmacokinetic study with one-hour intravenous infusion of doxifluiridine (5'-dFUrd) 3 g/m2 VS 5 g/m2 QD x 5 per month.
Topics: Adenocarcinoma; Antineoplastic Agents; Cecal Neoplasms; Colonic Neoplasms; Drug Evaluation; Drug Tol | 1986 |
Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Colonic Neoplasms; Female; Floxuridine; Hepat | 1987 |
Regional infusion for colorectal hepatic metastases. A randomized trial comparing the hepatic artery with the portal vein.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Female; Fl | 1987 |
A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Female; Floxurid | 1988 |
Adrenal function in patients treated with testosterone and fluorinated pyrimidines.
Topics: 17-Ketosteroids; Adenocarcinoma; Adrenal Cortex Hormones; Adrenal Glands; Adrenocorticotropic Hormon | 1968 |
180 other studies available for floxuridine and Adenocarcinoma
| Article | Year |
|---|---|
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Multiple; Drug R | 2011 |
An Unusual Mechanical Cause of Upper Gastrointestinal Hemorrhage.
Topics: Adenocarcinoma; Angiography; Antimetabolites, Antineoplastic; Catheters; Duodenal Diseases; Endoscop | 2021 |
[A Case of Long-Term Survival in a Patient with Small Intestinal Adenocarcinoma with Peritoneal Dissemination].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Floxuridine; | 2016 |
The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2016 |
Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biliary Tract Neopla | 2009 |
Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: is it essential for patients with ypT0-2N0?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2009 |
Cytostatic activity of the duplex drug linking 2'-deoxy-5-fluorouridine (5FdU) with 3'-C-ethynylcytidine (ECyd) against gastric adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tu | 2011 |
Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2012 |
The effect of locoregional transarterial infusion chemotherapy on liver metastasis after gastric cancer resection.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Floxuridine; Humans; I | 2012 |
[A case of recurrent gastric cancer that responded dramatically to docetaxel and 5'-DFUR combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr | 2002 |
[A case of colon metastasis to the lung treated successfully with combined chemotherapy of CPT-11 and 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Sc | 2002 |
Effectiveness of doxifluridine (5'-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm | 2002 |
[A case of multiple lung metastases of colon cancer with long-term survival following 5'-DFUR and cimetidine therapy].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Cimetidine; Colonic N | 2003 |
5-Fluorodeoxyuridine (adenocarcinoma, small bowel).
Topics: Adenocarcinoma; Antineoplastic Agents; Floxuridine; Humans; Intestine, Small; Intestines; Neoplasms | 1961 |
INCORPORATION OF I-125-LABELED IODODEOXYURIDINE INTO THE DEOXYRIBONUCLEIC ACID OF MURINE AND HUMAN TISSUES FOLLOWING THERAPEUTIC DOSES.
Topics: Adenocarcinoma; Animals; DNA; DNA, Neoplasm; Floxuridine; Geriatrics; Idoxuridine; Intestine, Small; | 1963 |
CONTINUOUS INTRA-ARTERIAL OR INTRAVENOUS INFUSION OF 5-FLUORO-2-DEOXYURIDINE: THERAPEUTIC AND TOXIC EFFECTS.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Squamous Cell; Carotid Arteries; Chemotherapy, Cancer, Regiona | 1963 |
ONCOLYSIS BY CLOSTRIDIA. III. EFFECTS OF CLOSTRIDIA AND CHEMOTHERAPEUTIC AGENTS ON RODENT TUMORS.
Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; Aziridines; Bacteriological Techniq | 1964 |
ACUTE GASTRITIS RESULTING FROM REGIONAL INFUSION OF AN ANTIMETABOLITE.
Topics: Adenocarcinoma; Angiography; Antimetabolites; Chemotherapy, Cancer, Regional Perfusion; Diagnosis, D | 1963 |
PROTRACTED ARTERIAL INFUSION CANCER CHEMOTHERAPY.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Squamous Cell; Carotid Arteries; Catheterization; Colonic Neop | 1964 |
FLUORINATED PYRIMIDINES. 23. FURTHER STUDIES ON NUCLEOSIDE PHOSPHORYLASE.
Topics: Adenocarcinoma; Animals; Carbon Isotopes; Carcinoma, Ehrlich Tumor; Enzyme Inhibitors; Floxuridine; | 1964 |
SYSTEMIC CHEMOTHERAPY FOR CNS METASTASES OF SOLID TUMORS.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy; Floxuridine; Fluo | 1965 |
[A case of multiple liver metastases of colon cancer with PyNPase-positive successfully treated with 5'-DFUR].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colectomy; Colonic Neoplasms; Combined Modali | 2003 |
[A case of hepatic metastasis and local recurrence from rectal cancer responding to hepatic arterial infusion and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat | 2003 |
[Two cases of metastatic or recurrent rectal cancer responding to combined chemotherapy of low-dose CPT-11 and 5'-DFUR as second-line chemotherapy].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2004 |
[A case of advanced gastric cancer successfully treated with neoadjuvant chemotherapy of combined weekly paclitaxel and doxifluridine (5'-DFUR)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug A | 2004 |
[Thymidine phosphorylase expressed in monocyte-macrophages enhanced anticancer effect of 5'-deoxy-5-fluorouridine on colorectal carcinoma cells].
Topics: Adenocarcinoma; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineopla | 2004 |
Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cam | 2004 |
[A case of liver metastasis of colon cancer responding remarkably to 5'-DFUR].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colon, Sigmoid; Combined Modality Therapy; Dr | 2004 |
[Antisense oligonucleotides with antitumor activity].
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Deoxyuridine; Fibrosarco | 2004 |
[A case of long-term survival after chemo-radiation for postoperative local recurrence of rectal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2004 |
[A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic | 2004 |
Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT.
Topics: Adenocarcinoma; Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Bile Duct Diseases; Biliru | 2005 |
[Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Color | 2005 |
[A case of recurrent gastric cancer effectively treated by combination chemotherapy of weekly paclitaxel and 5'- DFUR after showing resistance to weekly paclitaxel].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Moda | 2006 |
[A case of gastric cancer with multiple liver metastases resistant to TS-1 responding to chemotherapy with paclitaxel plus doxifluridine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat | 2006 |
[A case of local recurrence of rectal cancer in long-term responding to combined therapy of low-dose CPT-11 and 5'-DFUR].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2006 |
[A case of advanced gastric cancer--efficacy of combination therapy of doxifluridine and weekly paclitaxel].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Combined Modality Thera | 2006 |
[A treatment for pulmonary metastases from colorectal cancer by pre-operative CPT-11/5'-DFUR combination therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2006 |
Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptot | 2007 |
Penetrating duodenal ulcer associated with an operatively implanted arterial chemotherapy infusion catheter.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Catheters, Indwelling; Duodenal Ulcer; Floxuridine; Hep | 1982 |
Effective retreatment of patients with colorectal cancer and liver metastases.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Drug Resistan | 1983 |
Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality | 1983 |
Phase II study of doxifluridine in advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemical Phenomena; Chemistry; Colonic Neoplasms | 1983 |
Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Female; Floxuridine; Hepatic Artery; Humans; Infusio | 1984 |
[Effects of 5'-deoxy-5-fluorouridine on human gastrointestinal and breast cancers xenografted to nude mice].
Topics: Adenocarcinoma; Administration, Oral; Animals; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Femal | 1984 |
The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colonic Neoplasms; Floxuridine; Humans; Infusions, Intra- | 1981 |
On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice.
Topics: Adenocarcinoma; Animals; Cell Survival; Colonic Neoplasms; Female; Floxuridine; Fluorodeoxyuridylate | 1980 |
The use and limitations of serial plasma carcinoembryonic antigen (CEA) levels as a monitor of changing metastatic liver tumor volume in patients receiving chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoembryonic Antigen; Female; Floxuridine; H | 1980 |
Gastroduodenal ulceration after hepatic arterial infusion chemotherapy.
Topics: Adenocarcinoma; Colonic Neoplasms; Duodenal Ulcer; Female; Floxuridine; Hepatic Artery; Humans; Infu | 1981 |
Sequence of regional chemotherapy and surgery. Management of colorectal adenocarcinoma confined to the liver.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Colonic Neoplasms; Floxuridine; Humans; Liver Neoplasms; M | 1981 |
Hepatic artery dexamethasone infusion inhibits colorectal hepatic metastases: a regional antiangiogenic therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Capillaries; Cell Line; Che | 1995 |
[Combination therapy of doxifluridine, pirarubicin and cisplatin for human gastric cancers implanted in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cisplatin; Dox | 1995 |
[A case of advanced gastric cancer successfully treated with combination chemotherapy using THP, 5'-DFUR and CDDP, followed by surgical resection].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug A | 1995 |
[A successful 5'-DFUR and CDDP combination therapy for an advanced gastric cancer complicated with multiple liver metastases].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 1995 |
Isolated lung perfusion with FUDR is an effective treatment for colorectal adenocarcinoma lung metastases in rats.
Topics: Adenocarcinoma; Animals; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Female; Flo | 1995 |
[A case of pulmonary metastasis from colon cancer successfully treated with high-dose 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Agents; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Drug | 1995 |
[A case of advanced gastric cancer with liver metastasis disappeared by oral administration of 5'-deoxy-5-fluorouridine after absolute non-curative operation].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Floxuridi | 1994 |
[A case of recurrent breast cancer responding to combination therapy with mitoxantrone (MIT), 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA)].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1994 |
[A case of cutaneous and brain metastasis of gastric carcinoma, treated effectively by chemotherapy with CDDP, MMC, etoposide and 5'-DFUR].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 1994 |
The effects on liver metastases of circadian patterned continuous hepatic artery infusion of FUDR.
Topics: Adenocarcinoma; Animals; Catheterization, Peripheral; Circadian Rhythm; Drug Administration Schedule | 1994 |
[Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Fema | 1994 |
[A case of advanced gastric cancer with liver and lung metastasis effectively treated by combined chemo-immunotherapy of MMC, 5'-DFUR, OK-432].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dru | 1993 |
[A case of bilateral pulmonary metastasis from rectal cancer successfully treated with resection after high-dose 5'-DFUR plus MMC combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Flox | 1993 |
[A case of effective chemotherapy by combination of 5'-DFUR and MMC for recurrent colon cancer with multiple liver metastasis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms; Drug A | 1996 |
[PyNPase activity in primary and metastatic colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Floxuridine; Humans; L | 1997 |
Inhibitory effects of fluorinated pyrimidines, 5'-DFUR, UFT and T-506, in a model of hepatic metastasis of mouse colon 26 adenocarcinoma-assessment of inhibitory activity and adverse reactions at the maximum tolerated dose.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Colonic Neoplasms; Dose-Response Relati | 1997 |
[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Flo | 1997 |
[Combination therapy with 5'-DFUR, MMC and CDDP in patient with far advanced gastric cancer: report of a case].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; F | 1997 |
[Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 1997 |
[Successful treatment of hepatic metastasis of gastric cancer with 5'-DFUR and Lentinan].
Topics: Adenocarcinoma; Aged; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Drug Adm | 1998 |
[A CR case of amylase-producing tumor treated by hyperthermochemotherapy].
Topics: Adenocarcinoma; Amylases; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Floxu | 1998 |
Increased hepatic nicotinamide N-methyltransferase activity as a marker of cancer cachexia in mice bearing colon 26 adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cachexia; Colonic Neoplasms; Floxuridine; Liver; Methyltransferases; Mice; | 1998 |
Carcinoma of the stomach metastatic to the liver that progressed after hepatic arterial infusion of cisplatin plus 5-floxuridine, and then dramatically regressed after chemoembolization based on positive chromogranin staining.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic | 1999 |
[Combination of 5'-DFUR and MMC for recurrent rectal cancer with pulmonary metastasis].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1999 |
[A case of gastric carcinoma treated effectively with 5'-DFUR].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Cardia; Drug Administration Sched | 1999 |
Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes.
Topics: Adenocarcinoma; Cyclin D1; Drug Resistance, Neoplasm; Enzyme Induction; Floxuridine; Fluorouracil; G | 1999 |
Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Survival; Cloning, Molecular; Colorectal Neoplasms; DNA, | 1999 |
[Evaluation of antitumor activity of etoposide administered orally for 21 consecutive days against human uterine cancer subcutaneous and/or orthotopic xenografts in nude mice].
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytoge | 1999 |
[Successful treatment of pleuritis carcinomatosa using combination therapy of 5'-DFUR, MPA and CPA as maintenance therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 1999 |
[Long-term complete response in a case of unresectable rectal cancer following chemoradiation].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2000 |
[A case of diffusely infiltrating carcinoma of the sigmoid colon associated with lymphangitis carcinomatosa effectively treated with sequential MTX.5-FU and 5'-DFUR].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 2000 |
Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Floxuridine; H | 2000 |
Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dexamethasone; | 2000 |
Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Data Interpret | 2000 |
Intra-abdominal fibrosis after systemic and intraperitoneal therapy containing fluoropyrimidines.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; | 2000 |
Effect of a fluorinated pyrimidine on cachexia and tumour growth in murine cachexia models: relationship with a proteolysis inducing factor.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Appetite Stimulants; Blood Proteins; Body | 2000 |
Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
Topics: Abdominal Pain; Adenocarcinoma; Antimetabolites, Antineoplastic; Ascites; Catheters, Indwelling; Chr | 2000 |
[Effectiveness of high-dose, intermittent 5'-DFUR therapy for advanced gastric cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Administrati | 2001 |
Three-dimensional organization of the hepatic microvasculature in hereditary hemorrhagic telangiectasia.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiography; Antimetabolites, Antineoplastic; Autopsy; Biop | 2001 |
Surgery as adjuvant therapy? The treatment of peritoneal metastases from gastrointestinal malignancy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Colonic Neopl | 2001 |
Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2001 |
Fighting wars, winning battles.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2002 |
Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Survival; Colonic Neoplasms; Combined | 2002 |
[A case report of effective chemoradiation with 5'-DFUR and concomitant preoperative radiotherapy of the lower rectum].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Administration Schedule; Female; Floxuridine; | 2002 |
The chemotherapy of urologic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Doxorubicin; Drug Therapy, Co | 1975 |
A new micromethod for the detection of HL-A antigens on cultured human tumor cells.
Topics: Adenocarcinoma; Antibody Specificity; Colonic Neoplasms; Culture Techniques; Cytotoxicity Tests, Imm | 1975 |
Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary.
Topics: Adenocarcinoma; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusi | 1979 |
Current status of regional arterial infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; | 1975 |
In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Survival; Colony-Forming Units Assay; Colorecta | 1992 |
[A case of multiple pulmonary metastases from duodenal cancer showing partial response using 5'-DFUR and a small dose of MMC].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Duodenal Neoplasms; Female; Fl | 1992 |
[A case report; 5'-DFUR reduced gastric cancer with multiple liver metastasis].
Topics: Adenocarcinoma; Antineoplastic Agents; Floxuridine; Humans; Liver Neoplasms; Male; Middle Aged; Stom | 1992 |
[A case of gastric cancer with recurrent bone metastases successfully treated with induced hypertension chemotherapy using cisplatin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Bone and Bones | 1992 |
In vivo antitumor effects of fluoropyrimidines on colon adenocarcinoma 38 and enhancement by leucovorin.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Cell Div | 1992 |
The effect of liver macrophages on in vitro cytolytic activity of 5FU and FUdR on colon carcinoma cells: evidence of macrophage activation.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adenocarcinoma; Animals; Colonic Neoplasms; Cytotoxicity, Immunol | 1992 |
[Two cases of pulmonary metastasis of colorectal cancer successfully treated with oral 5'-DFUR].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Drug Administration Schedule; Fem | 1992 |
[Phase II study of 5'-DFUR in uterine cervical cancer and ovarian cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Administration, Oral; Adult; Aged; Antineoplastic Agents; | 1991 |
Anticachectic activity of 5'-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma.
Topics: Acute-Phase Proteins; Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cachexia; C | 1990 |
[5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Etoposide; Female; | 1991 |
Comparative DNA strand breakage induced by FUra and FdUrd in human ileocecal adenocarcinoma (HCT-8) cells: relevance to cell growth inhibition.
Topics: Adenocarcinoma; Cell Division; Colonic Neoplasms; DNA; DNA Damage; Dose-Response Relationship, Drug; | 1991 |
[5-Fluorouracil level and pyrimidine nucleoside phosphorylase activity in cancer patients after oral administration of doxifluridine (5'-DFUR)].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Colonic Neop | 1991 |
Prostaglandin E1 enhances tumoricidal activity of 5-fluoro-2'-deoxyuridine in rats.
Topics: Adenocarcinoma; Alprostadil; Animals; Antineoplastic Agents; Body Weight; Drug Synergism; Floxuridin | 1991 |
[Phase II study of 5'-DFUR (Furtulon) capsule for bladder cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Squamous | 1991 |
[A case of pulmonary metastasis from colon cancer responding completely to high-dose 5'-DFUR plus MMC combination chemotherapy].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic | 1991 |
5'-Deoxy-5-fluorouridine improves cachexia by a mechanism independent of its antiproliferative action in colon 26 adenocarcinoma-bearing mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cachexia; Cell Division; Colonic Neoplasms; Drug Res | 1991 |
Determination of the therapeutic index of floxuridine by its circadian infusion pattern.
Topics: Adenocarcinoma; Animals; Circadian Rhythm; Data Interpretation, Statistical; Drug Administration Sch | 1990 |
Differential effects of 2,2'-anhydro-5-ethyluridine, a uridine phosphorylase inhibitor, on the antitumor activity of 5-fluorouridine and 5-fluoro-2'-deoxyuridine.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Interactions; Floxuridine; Fluorouracil; Humans; Ki | 1990 |
[A study on preoperative administration of doxifluridine in carcinoma of the colon and rectum].
Topics: Adenocarcinoma; Administration, Oral; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Lymph | 1990 |
Role for cytosolic folate-binding proteins in the compartmentation of endogenous tetrahydrofolates and the 5-formyl tetrahydrofolate-mediated enhancement of 5-fluoro-2'-deoxyuridine antitumor activity in vitro.
Topics: Adenocarcinoma; Animals; Carrier Proteins; Cell Division; Chromatography, Gel; Colonic Neoplasms; Fl | 1990 |
Relationship between dose rate of [6RS]Leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Female; Floxuridine; Half-Life; Humans; Injections, Intr | 1990 |
[A progressive gastric cancer in which preoperative oral chemotherapy resulted in a histopathological "Grade 2" rating].
Topics: Adenocarcinoma; Antineoplastic Agents; Combined Modality Therapy; Drug Administration Schedule; Flox | 1990 |
Optimal treatment regimens for 5'-deoxy-5-fluorouridine, with or without (E)-5-(2-bromovinyl)-2'-deoxyuridine, against various tumors in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antiviral Agents; Bromodeoxyuridine; Colonic Neoplas | 1990 |
Gastroduodenal artery-duodenal fistula: a complication of continuous floxuridine (FUDR) infusion into the gastroduodenal artery.
Topics: Adenocarcinoma; Arteries; Duodenal Diseases; Duodenum; Fistula; Floxuridine; Gastrointestinal Hemorr | 1990 |
[A resected case of gastric carcinoma with complete remission of Virchow's node metastasis by 5'-DFUR administration].
Topics: Adenocarcinoma; Antineoplastic Agents; Combined Modality Therapy; Female; Floxuridine; Gastrectomy; | 1990 |
[A markedly effective combination therapy of 5'-DFUR and MMC in advanced gastric cancer--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Floxuridine; Humans; M | 1990 |
Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human lung cancer cell lines.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma, Squamous Cell; Cell Line; Dose-Respo | 1990 |
Increased growth inhibition and DNA lesions in human colon adenocarcinoma cells treated with methotrexate or 5-fluorodeoxyuridine followed by calmodulin inhibitors.
Topics: Adenocarcinoma; Bleomycin; Calmodulin; Cell Survival; Colonic Neoplasms; DNA Damage; Floxuridine; Hu | 1988 |
Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Division; Drug Synergism; Floxuridine; Fluorou | 1988 |
Mechanisms of potentiation of antitumor activity of 5-fluoro-2'-deoxyuridine in the adenocarcinoma 755 system by guanosine 5'-monophosphate.
Topics: Adenocarcinoma; Animals; Chromatography, High Pressure Liquid; Drug Synergism; Floxuridine; Guanine | 1988 |
Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Aspartate Aminotransferases; Bilirubin; Colorecta | 1989 |
5-Fluoropyrimidine-induced DNA damage in human colon adenocarcinoma and its augmentation by the nucleoside transport inhibitor dipyridamole.
Topics: Adenocarcinoma; Colonic Neoplasms; Dipyridamole; DNA; DNA Damage; Floxuridine; Fluorouracil; Humans; | 1989 |
Enhanced antitumor effect of 5'-deoxy-5-fluorouridine by oral administration with L-cysteine.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Chrom | 1989 |
[Two cases of gastrointestinal cancers with major responses to sequential methotrexate 5-FU plus 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Ne | 1989 |
Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bromodeoxyuridine; Chromatography, High Pressure Liq | 1989 |
MTX-5-FU combination therapy compared to FUDR monotherapy in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; | 1989 |
Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colony-Forming Un | 1989 |
Intra-arterial hepatic chemotherapy for metastatic liver from colo-rectal carcinoma origin.
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery | 1989 |
Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Colonic Neoplasms; Combined Modality Th | 1989 |
[A case of multiple pulmonary metastases from rectal cancer which responded completely to combination chemotherapy using 5'-DFUR and MMC].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Tolerance; Floxuridine; H | 1989 |
[In vitro studies of 5-FU sensitivity on uterine cervical cancer cell lines--comparison between squamous cell carcinoma and adenocarcinoma].
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cell Survival; DNA, Neoplasm; Drug Screening Assays, Antit | 1989 |
Phase I-II trial of doxifluridine (5'DFUR) administered as long-term continuous infusion using a portable infusion pump for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Female; Flox | 1989 |
Hepatic perfusion with FUdR utilizing an implantable system in patients with liver primary cancer or metastatic cancer confined to the liver.
Topics: Adenocarcinoma; Adenoma, Bile Duct; Adult; Aged; Carcinoma, Hepatocellular; Colorectal Neoplasms; Fl | 1989 |
Hepatic arterial flow distribution with hepatic neoplasms: significance in infusion chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1987 |
[Furtulon (doxifluridine) in the treatment of non-small cell bronchial carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small | 1987 |
[A case of remission of metastatic gastric cancer lesions in the chest and abdominal wall by 5'-DFUR administration].
Topics: Abdominal Muscles; Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Female; Floxuridine; | 1985 |
Acute cholecystitis associated with hepatic arterial infusion of floxuridine.
Topics: Acute Disease; Adenocarcinoma; Cholecystitis; Female; Floxuridine; Humans; Infusions, Intra-Arterial | 1985 |
Common duct stricture associated with hepatic artery infusion of FUDR.
Topics: Adenocarcinoma; Colonic Neoplasms; Common Bile Duct Diseases; Constriction, Pathologic; Floxuridine; | 1986 |
[Comparison of the performance of a totally implantable pump and conventional access systems in regional arterial chemotherapy of liver tumors].
Topics: Adenocarcinoma; Aged; Carcinoma; Carcinoma, Squamous Cell; Female; Floxuridine; Humans; Infusions, I | 1986 |
On the differential affinities of two anticancer analogues to their target.
Topics: Adenocarcinoma; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; Floxuridine; Fluoro | 1985 |
Fluorodeoxyuridine uptake by human colorectal hepatic metastases after hepatic artery infusion.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Female; Floxuridine; Hepatic Artery; Humans; Infusions, Int | 1986 |
Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.
Topics: Adenocarcinoma; Aged; Brain Diseases; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial | 1986 |
Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma.
Topics: Adenocarcinoma; Cells, Cultured; Colonic Neoplasms; Floxuridine; Fluorine; Fluorouracil; Humans; Mac | 1986 |
Causes of jaundice during hepatic artery infusion chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Bile Ducts, Intrahepatic; Colonic Neoplasms; Female; Floxuridine; Human | 1986 |
Endoscopic biliary stent placement for bile duct stricture after hepatic artery infusion of 5-FUDR.
Topics: Adenocarcinoma; Aged; Catheters, Indwelling; Cholestasis, Extrahepatic; Cholestasis, Intrahepatic; C | 1986 |
Sclerosing cholangitis from intraarterial floxuridine.
Topics: Adenocarcinoma; Aged; Bile Ducts; Cholestasis, Intrahepatic; Female; Floxuridine; Hepatic Artery; Hu | 1986 |
A complication of prolonged infusional chemotherapy masquerading as a bone metastasis in a patient with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Bone Neoplasms; Catheterization; Floxuridine; Humans; Liver Neoplasms; Male; | 1987 |
Comparative antitumor activity of ruthenium derivatives with 5'-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Dimethylnitrosamine; Floxuridine; Imidazoles; Male; Orga | 1987 |
Excretion of doxifluridine catabolites in human bile assessed by 19F NMR spectrometry.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Bile; Colonic Neoplasms; Floxuridine; Humans; Magnetic | 1987 |
Judging causality.
Topics: Adenocarcinoma; Cholestasis, Intrahepatic; Colonic Neoplasms; Floxuridine; Humans; Infusions, Intra- | 1987 |
Myocardial ischemia with fluorouracil and floxuridine therapy.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Coronary Disease; Electrocardiography; Floxuridine; Fluorou | 1987 |
[Locoregional chemotherapy of hepatic metastases of colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Infusion Pumps; I | 1987 |
Liposomes in chemo- and immunotherapy of cancer.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adenocarcinoma; Animals; Floxuridine; Liposomes; Liver; Liver Neo | 1987 |
Increased levels of DNA lesions induced by leucovorin-5-fluoropyrimidine in human colon adenocarcinoma.
Topics: Adenocarcinoma; Aphidicolin; Cell Line; Cell Survival; Colonic Neoplasms; Diterpenes; DNA; DNA Damag | 1988 |
Penetrating duodenal ulcer from hepatic artery chemotherapy infusion catheter. Successful conservative medical management.
Topics: Adenocarcinoma; Catheters, Indwelling; Duodenal Ulcer; Female; Floxuridine; Hepatic Artery; Humans; | 1988 |
[Clinical phase II study of 5'-DFUR for cancer of the digestive organs by a cooperative study group].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colo | 1985 |
Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induc | 1985 |
Hepatobiliary scintigraphy in patients receiving hepatic artery infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cholecystitis; Colonic Neoplasms; Do | 1985 |
[Clinical phase II study of TK-117 by Cooperative Study Group. Effects on gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Floxuridin | 1985 |
Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine in the HCT-8 human carcinoma line.
Topics: Adenocarcinoma; Biological Transport; Cell Line; Colonic Neoplasms; Diffusion; Drug Resistance; Flox | 1985 |
Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Cell Line; Col | 1985 |
Iatrogenic sclerosing cholangitis following hepatic arterial chemotherapy infusion.
Topics: Adenocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis; Colonic Neoplasms; Flo | 1985 |
The treatment of hepatic metastases by long-term chemotherapeutic infusions.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Colonic Neoplasms; Evaluation Studies as Topic; Female; | 1970 |
3',5'-diesters of 5-fluoro-2'-deoxyuridine: synthesis and biological activity.
Topics: Adenocarcinoma; Animals; Chemical Phenomena; Chemistry; Chromatography; Floxuridine; Houseflies; Ins | 1965 |
Infusion of fluorinated pyrimidines into hepatic artery for treatment of metastatic carcinoma of liver.
Topics: Adenocarcinoma; Catheterization; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Hepatic Arte | 1967 |
Responses of freshly cultured tumour cells to certain selected chemotherapeutic agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Chlorambucil; Colchicine; Culture Techniques; Cyclophosphamid | 1968 |
Use of 5-fluorodeoxyuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Floxuridine; Gastrectomy; Humans; Male; Methods; Middle Aged; Postopera | 1969 |
Effect of resection of the primary neoplasm on responsiveness to chemotherapy of patients with large bowel cancer.
Topics: Adenocarcinoma; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Nitrosourea Compounds; Rectal | 1972 |
5-Fluorouracil and derivatives in cancer chemotherapy. 3. In vivo enhancement of antitumor activity of 5-fluorouracil (FU) and 5-fluoro-2'-deoxyuridine (FUDR).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chromatography, Thin Layer; Deoxycytidine; Deoxyurid | 1973 |
Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Bile Duct Neoplasms; Evaluation Studies as Topic; Floxuridine | 1974 |
Clinical evaluation of 5-bromo-5-fluoro-6-methoxy-dihydro-2'-deoxyuridine.
Topics: Adenocarcinoma; Adult; Aged; Animals; Bromodeoxyuridine; Carcinoma; Carcinoma, Hepatocellular; Carci | 1967 |